<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100829004655N12</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-05-04</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effects of acupressure points on patients undergoing chemotherapy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effects of acupressure points (P6, K-K9) on Nausea, Vomiting and anxiety of patients undergoing chemotherapy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69884</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Other design features: Demographic information obtained includes first and last name, date of injection, age, gender, marital status, economic status, occupation, education, type of insurance, family history of cancer, alcohol consumption, and smoking and tobacco use. The obtained clinical information, which is completed by the patient or by referring to the medical record, also includes diagnosis, stage of the disease, duration of the disease, the number of cycles of chemotherapy, the method of receiving chemotherapy, the name and dosage of chemotherapy drugs. Treatment is the degree of nausea of the drugs, the name of the anti-nausea drugs and the dose received in the hospital and at home, the name of other drugs used, body mass index, history of surgery related to cancer, and other complications related to chemotherapy. If the patient needs help to complete the questionnaires, they will be completed by the researcher in the hospital.The drugs used as anti-nausea in these patients will be 4mg ondansetron ampoule, 8mg dexamethasone ampoule, and Aprepitant oral capsule. It should be noted that during the study, each patient's chemotherapy and anti-nausea regimen will not change. The use of drugs to relieve nausea other than the mentioned drugs, if used in the hospital by the researcher and if used at home by the patient and in a checklist that we provide to him, will be registered.The exact location of acupressure points is taught to the patient by the researcher, and for this purpose, a pamphlet is also given to her to help her find the point at home, Randomization description: After reviewing the entry criteria (referring to the medical record and interviewing the individual), patients who are eligible to enter the study are randomly grouped. Each patient is placed in one of the groups P6, K-K9 and Li5 (placebo) according to the nausea-inducing level of chemotherapy drugs (low, medium and high). It should be noted that according to the table of nausea-inducing drugs, 4 general categories are considered for chemotherapy drugs, which include Minimal Risk of Emesis, Low Risk of Emesis, Moderate Risk of Emesis, and High Risk of Emesis. The minimal risk of emesis category is not included in the study.
For example, the first qualified referral patient is treated with a three-drug regimen of 5FU (Fluorouracil), oxaliplatin and docetaxel; According to the table, these drugs are mild, moderate nauseating, and low nauseating. Due to the presence of a drug with moderate nausea (oxaliplatin), this patient is considered out of this category (moderate nausea). Referring to the blocks, this person is placed in group B, the same as K-K9. If the next person is considered part of the moderate nausea group, he will be placed in group A, the same group as P6. In the same way, the following people are assigned to three groups, P6, K-K9, and Li5, according to whether the amount of nausea caused by their drugs is low, medium, or high.
Allocation of groups is done randomly using the stratified method based on the degree of nausea of the drugs and using the Sealedenvelope.com site. In this method, the size of the blocks is considered to be 6. The size of the list is considered to be 126 due to the equal distribution of each class among the three groups. In fact, by increasing the list size, samples from other classes can be included in the study if a class does not reach the quorum, Blinding description: Due to the interventions' observable nature, it is impossible to design the study in a completely blind manner. In this study, after giving informed consent to participate in the research, the participants will not know whether they are in the placebo group or the main groups, so the main names of the points are not told to the participants. Instead, general names such as A, B, and C are used. As a research team member, the nursing master's student is responsible for implementing interventions and collecting questionnaires and checklists, so there is no possibility of blinding in this case. The healthcare workers in the special injection ward of Shahid Beheshti Hospital in Kashan (including nurses) also do not know about the real intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>chemotherapy.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: pressure on the P6 point will be applied bilaterally by acupressure wrist straps. The wristbands are from the vomit-band brand and consist of a webbing with a button in the middle that puts pressure on the P6 point. Acupressure intervention will be done before chemotherapy until five days after. The patient is asked to remove the acupressure tools at the end of the day and before going to sleep and complete the special checklists designed for this study. The next day, he should use that tool again in the same place. This process should be done five days after the injection. It should be noted that he can remove them from his hands during bathing, washing hands, etc. After five days, the patient does not need to do anything else. Intervention 2: The second intervention group: Applying pressure on the K-K9 point is done bilaterally by rings made of knitted fabric with a button in the middle (similar to the button of P6 wristbands). Acupressure intervention will be done before chemotherapy until five days after. The patient is asked to remove the acupressure tools at the end of the day and before going to sleep and complete the special checklists designed for this study. The next day, he should use that tool again in the same place. This process should be done five days after the injection. It should be noted that he can remove them from his hands during bathing, washing hands, etc. After five days, the patient does not need to do anything else. Intervention 3: Control group: Applying pressure on the Li5 point (placebo) using knitted wristbands, which apply pressure on the desired point bilaterally. The button that puts pressure on this point is similar to that on P6 wristbands. Acupressure intervention will be done before chemotherapy until five days after. The patient is asked to remove the acupressure tools at the end of the day and before going to sleep and complete the special checklists designed for this study. The next day, he should use that tool again in the same place. This process should be done five days after the injection. It should be noted that he can remove them from his hands during bathing, washing hands, etc. After five days, the patient does not need to do anything else.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The total potential data can be shared after unidentifiable people

When:
Start the access period 6 months after printing the results

To whom:
Only available to scholars working in academia and academia.

Conditions:
If you observe the trust and mention the source, data is available for researchers

Where to obtain:
Send the following e-mail to the following address: taghadosi_m@kaums.ac.ir

How to obtain:
After receiving the letter via email, your request will be reviewed within 2 weeks and the data will be sent to the applicant at the discretion.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohsen Taghadosi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ravandi Ghotb Blvd</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>87159/81151</zip>
        <telephone>+98 31 5554 0021</telephone>
        <email>taghadosi_m@kaums.ac.ir</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohsen Taghadosi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ravandi Ghotb Blvd</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>87159/81151</zip>
        <telephone>+98 31 5554 0021</telephone>
        <email>taghadosi_m@kaums.ac.ir</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 16 years and older
Patients with a definitive diagnosis of breast, colorectal, lung, prostate, and ovarian cancers by a specialist doctor
Patients who mention having nausea in their previous chemotherapy period
Patients who receive chemotherapy drugs by intravenous, port, or intravenous injection along with oral intake
Patients who have received at least one cycle of chemotherapy</inclusion_criteria>
      <agemin>16 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Undergoing radiotherapy at the same time as chemotherapy
Using other complementary treatments at the same time
Having a known anxiety disorder
Having problems in the skin of acupressure points (for example, edema, lesions, or skin wounds) so that effective pressure cannot be applied
Having problems such as gastrointestinal diseases with nausea and vomiting, migraines, and tinnitus that are related to before the start of chemotherapy and interfere with nausea and vomiting of chemotherapy. This case will be reviewed based on the patient's statement or medical record
Patients who have a minimal risk of emesis chemotherapy regimen as determined by a specialist doctor.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z54.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Convalescence following chemotherapy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: pressure on the P6 point will be applied bilaterally by acupressure wrist straps. The wristbands are from the vomit-band brand and consist of a webbing with a button in the middle that puts pressure on the P6 point. Acupressure intervention will be done before chemotherapy until five days after. The patient is asked to remove the acupressure tools at the end of the day and before going to sleep and complete the special checklists designed for this study. The next day, he should use that tool again in the same place. This process should be done five days after the injection. It should be noted that he can remove them from his hands during bathing, washing hands, etc. After five days, the patient does not need to do anything else.</i_keyword>
      <i_keyword>The second intervention group: Applying pressure on the K-K9 point is done bilaterally by rings made of knitted fabric with a button in the middle (similar to the button of P6 wristbands). Acupressure intervention will be done before chemotherapy until five days after. The patient is asked to remove the acupressure tools at the end of the day and before going to sleep and complete the special checklists designed for this study. The next day, he should use that tool again in the same place. This process should be done five days after the injection. It should be noted that he can remove them from his hands during bathing, washing hands, etc. After five days, the patient does not need to do anything else.</i_keyword>
      <i_keyword>Control group: Applying pressure on the Li5 point (placebo) using knitted wristbands, which apply pressure on the desired point bilaterally. The button that puts pressure on this point is similar to that on P6 wristbands. Acupressure intervention will be done before chemotherapy until five days after. The patient is asked to remove the acupressure tools at the end of the day and before going to sleep and complete the special checklists designed for this study. The next day, he should use that tool again in the same place. This process should be done five days after the injection. It should be noted that he can remove them from his hands during bathing, washing hands, etc. After five days, the patient does not need to do anything else.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea, whose score is measured by the Rhodes Nausea and Vomiting Questionnaire (statements 4, 5, and 7). Timepoint: One hour after chemotherapy and at the end of the first to fifth days of chemotherapy. Method of measurement: The Rhodes Nausea and Vomiting Questionnaire.</prim_outcome>
      <prim_outcome>Vomiting, whose score is measured by the Rhodes Nausea and Vomiting Questionnaire (statements 1, 3, and 6). Timepoint: One hour after chemotherapy and at the end of the first to fifth days of chemotherapy. Method of measurement: The Rhodes Nausea and Vomiting Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Anxiety is measured by Spielberger's state-trait anxiety questionnaire. Timepoint: One hour after chemotherapy and at the end of the first to fifth days of chemotherapy. Method of measurement: The Spielberger's state-trait anxiety questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-04-09</approval_date>
        <contact_name>Research Ethics committees of Faculty of Medicine and Faculty of Dentistry- Kashan University of Med</contact_name>
        <contact_address>Ghotb Ravandi Blvd, Kashan Kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
